CLL

Relapsed or Refactory

Criteria to qualify for study: Drug used in study:
  • CD20 positive
  • Must have at least on bi-dimensionally measurable lesion ≥ 1.5 cm.
  • Must have had at least one prior anti­cancer treatment.

SCRI  HEMREF-34

An Open-Label, Phase lb Study of IPI-145 in combination with Bendamustine, Rituximab or Bendamustine/Rituximab in Select Subjects with
Lymphoma or Chronic Lymphocytic Leukemia

 

 

 

 

 

 

Criteria to qualify for study: Drug used in study:
  • Must be CD5, CD19/20, and CD23 positive 
  • Cannot have more than 55% of circulating lymphocytes 
  • Lymphocyte count at diagnosis must be at least 5 x 103/µL

CLL 23 SCRI GP28331 Genentech

A Phase Ib Multicenter Dose-Finding and Safety Study of GDC-0199 and Obinutuzumab in Patients with Relapsed or Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)